Benzinga  Nov 17  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced it will be expanding its facilities by opening a satellite office on Gateway Boulevard in South San...
Benzinga  Nov 5  Comment 
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced the first patient has received its investigational new drug, PEGPH20 in combination with Merck's KEYTRUDA (pembrolizumab) in a clinical trial to determine the maximum tolerated dose of...
Benzinga  Sep 22  Comment 
Analysts at Barclays initiated coverage on ISIS Pharmaceuticals, Inc. (NASDAQ: ISIS) with a Equal-weight rating. The target price for ISIS Pharmaceuticals is set to $60. ISIS Pharmaceuticals shares closed at $50.20 on Monday. RBC Capital...
Motley Fool  Sep 12  Comment 
Mr. Market sends shares lower after the company reports good news. Could this be a buying opportunity?
Motley Fool  Aug 29  Comment 
This small-cap biotech has been crushing the markets for years. Does it deserve a place in your portfolio?
TheStreet.com  Aug 11  Comment 
NEW YORK (TheStreet) -- Halozyme shares are up by 7.77% to $22.75 in early afternoon trading on Tuesday, following the release of the biopharmaceutical company's 2015 second quarter earnings results yesterday. The San Diego, CA-based company...
Benzinga  Jul 31  Comment 
Eisai Co., Ltd. (OTC: ESALY) and Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that they have signed a clinical collaboration agreement to evaluate Eisai'santicancer agent eribulin mesylate (brand name: Halaven, "eribulin") in...



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki